|
|
|
Volumn 2, Issue 5, 2001, Pages 622-623
|
|
Genvir Flamel Technologies
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ACICLOVIR;
FAMCICLOVIR;
VALACICLOVIR;
CLINICAL TRIAL;
CONTROLLED RELEASE FORMULATION;
DOSE RESPONSE;
DRUG ABSORPTION;
DRUG APPROVAL;
DRUG BIOAVAILABILITY;
DRUG DELIVERY SYSTEM;
DRUG EFFICACY;
DRUG HALF LIFE;
DRUG METABOLISM;
DRUG USE;
EUROPE;
FRANCE;
GENITAL HERPES;
HERPES VIRUS INFECTION;
HERPES ZOSTER;
HUMAN;
REVIEW;
SIDE EFFECT;
SMALL INTESTINE;
SUSTAINED DRUG RELEASE;
UNITED STATES;
ACYCLOVIR;
ANIMALS;
ANTIVIRAL AGENTS;
CHICKENPOX;
DNA-DIRECTED DNA POLYMERASE;
ENZYME INHIBITORS;
HERPES SIMPLEX;
HUMANS;
THYMIDINE KINASE;
|
|
EID: 0034985932
PISSN: 09678298
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (4)
|
|
References (12)
|
